Market Insight - Strategies for success in India
This article was originally published in Scrip
The impressive growth of the Indian pharmaceutical market is accompanied by uncertainty around its IP/regulatory environment, disease trends, prescription patterns, domestic R&D capabilities, healthcare spending, and enablers like health insurance and the distribution infrastructure. These market factors tend to influence each other, complicating the picture of the future for the market.
You may also be interested in...
One year after acquiring Piramal's Domestic Formulations business in a deal that made it India's largest pharmaceutical player, Abbott remains confident about its growth prospects in India, where it hopes to be generating $2.5 billion in sales by 2020. But facing fierce competition from domestic firms, Abbott isn't about to get complacent, Michael Warmuth, senior VP of the company's Established Products Division, tells Pete Chan. This article is part of the 2011 Scrip Asia 100.
Asia life science-focused VC firms*
Roche is overhauling its cost structure to produce a leaner organisation better equipped to focus on the business of pharmaceutical innovation. It is also investing heavily in China, turning its Shanghai operations into a centre for everything from commercial manufacturing and research to partnering, licensing and strategic planning. Pascal Soriot, chief operating officer of Roche Pharmaceuticals, speaks to Pete Chan in an exclusive interview.